Orthostatic intolerance: Lightheaded upon standing, especially in warm environments or after a hot shower, can happen because the adrenaline/noradrenaline spikes arent regulated normally
Vascular alterations encountered in these patients were sinusoidal dilatation and nodular regenerative hyperplasia
Yes, IV drips can safely complement facials, peels, or laser sessions
Ghandi M, Huang FW, Jane-Valbuena J, Kryukov GV, Lo CC, McDonald ER 3rd, et al
& Davidoff, M
In Embodiment 8 of this disclosure are compounds of Formula I, or any one of Embodiments 1-7 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 In Embodiment 9 of this disclosure are compounds of Formula I, or any one of Embodiments 1-8 or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is (1) phenyl unsubstituted or substituted with 1, 2, or 3 R 7 , (2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N, O, and S, wherein the heteroaryl is unsubstituted or substituted with 1, 2, or 3 R 7 , (3) C 1-6 alkyl unsubstituted or mono-substituted, disubstituted, or trisubstituted with halogen, OH, CF 3 , CN, deuterium, or (C 3-6 )cycloalkyl, (4) (C 3-6 )cycloalkyl unsubstituted or optionally mono-substituted, disubstituted or trisubstituted with C 1-6 alkyl, halogen, OH, CF 3 , or CN, (5) (C 3-6 )alkylC(O)NH 2 , (6) 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted by 1, 2, or 3 R 7 , (7) CH 2 -heteroaryl unsubstituted or substituted by 1, 2, or 3 R 7 , (8) CH 2 -aryl unsubstituted or substituted by 1, 2, or 3 R 7 , (9) CH 2 -heterocyclyl unsubstituted or substituted by 1, 2, or 3 R 7 , (10) C(O) (C 1-6 )alkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (11) C(O) (C 3-6 )cycloalkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (12) C(O) (C 1-6 )heterocyclyl unsubstituted or substituted with 1, 2, or 3 R 7 , (13) C(O) aryl unsubstituted or substituted with 1, 2, or 3 R 7 , (14) SO 2 (C 1-6 )alkyl unsubstituted or substituted with 1, 2, or 3 R 7 (15) SO 2 (C 3-6 )cycloalkyl unsubstituted or substituted with 1, 2, or 3 R 7 , (16) SO 2 -aryl unsubstituted or substituted with 1, 2, or 3 R 7 , In Embodiment 10 of this disclosure are compounds of Formula I, or Embodiments 1-9, or a class thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is (1) phenyl unsubstituted or substituted with 1, 2, or 3 R 7 , (2) 5- or 6-membered heteroaryl containing 1, 2 or 3 heteroatoms independently selected from N and S, wherein the heteroaryl is unsubstituted or substituted with 1 or 2 halogen, C 1-3 alkyl, or cyclopropyl, (3) C 1-6 alkyl unsubstituted or mono-substituted, disubstituted, or trisubstituted with halogen, OH, CF 3 , CN, deuterium, or (C 3-6 )cycloalkyl, (4) (C 3-6 )cycloalkyl unsubstituted or optionally mono-substituted, disubstituted or trisubstituted with halogen, C 1-6 alkyl, OC 1-3 haloalkyl, OH, CF 3 , or CN, (5) (C 3-6 )alkylC(O)NH 2 , (6) 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S wherein the heterocyclyl is unsubstituted or substituted with 1 or 2 substituents selected from CH 3 or oxo, (7) CH 2 -heteroaryl unsubstituted or substituted with 1 or 2 methyl substituents, (8) CH 2 -aryl, (9) CH 2 -heterocyclyl, (10) C(O) (C 1-6 )alkyl, (11) C(O) (C 3-6 )cycloalkyl, (12) C(O) (C 1-6 )heterocyclyl, (13) C(O) aryl, (14) SO 2 (C 1-6 )alkyl, or (15) SO 2 (C 3-6 )cycloalkyl
